Aldeyra Therapeutics Future Growth

Future criteria checks 5/6

Aldeyra Therapeutics is forecast to grow earnings and revenue by 71.6% and 55.5% per annum respectively. EPS is expected to grow by 72% per annum. Return on equity is forecast to be -17.4% in 3 years.

Key information

71.6%

Earnings growth rate

72.0%

EPS growth rate

Biotechs earnings growth	27.6%
Revenue growth rate	55.5%
Future return on equity	-17.4%
Analyst coverage	Good
Last updated	16 Dec 2024

Recent future growth updates

Recent updates

Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment

Sep 14

Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization

Aug 04

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?

Aug 03

Aldeyra says trial for dry eye disease candidate reached key goals

Jul 12

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Apr 19

Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts

Feb 17

Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap

Dec 23

Earnings and Revenue Growth Forecasts

NasdaqCM:ALDX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	57	-14	-40	N/A	5
12/31/2025	65	-4	-62	N/A	8
12/31/2024	N/A	-54	-47	N/A	8
9/30/2024	N/A	-45	-31	-31	N/A
6/30/2024	N/A	-38	-31	-31	N/A
3/31/2024	N/A	-30	-31	-31	N/A
12/31/2023	N/A	-38	-30	-30	N/A
9/30/2023	N/A	-46	-42	-42	N/A
6/30/2023	N/A	-52	-47	-47	N/A
3/31/2023	N/A	-61	-53	-53	N/A
12/31/2022	N/A	-62	-57	-57	N/A
9/30/2022	N/A	-65	-57	-57	N/A
6/30/2022	N/A	-66	-53	-53	N/A
3/31/2022	N/A	-63	-42	-42	N/A
12/31/2021	N/A	-58	-43	-43	N/A
9/30/2021	N/A	-53	-39	-39	N/A
6/30/2021	N/A	-46	-37	-37	N/A
3/31/2021	N/A	-39	-36	-36	N/A
12/31/2020	N/A	-38	-37	-37	N/A
9/30/2020	N/A	-39	-40	-40	N/A
6/30/2020	N/A	-49	-42	-42	N/A
3/31/2020	N/A	-55	-48	-48	N/A
12/31/2019	N/A	-61	-45	-45	N/A
9/30/2019	N/A	-58	-42	-42	N/A
6/30/2019	N/A	-50	-41	-41	N/A
3/31/2019	N/A	-46	-35	-35	N/A
12/31/2018	N/A	-39	-30	-30	N/A
9/30/2018	N/A	-35	-27	-27	N/A
6/30/2018	N/A	-29	N/A	-24	N/A
3/31/2018	N/A	-26	N/A	-23	N/A
12/31/2017	N/A	-22	N/A	-19	N/A
9/30/2017	N/A	-20	N/A	-18	N/A
6/30/2017	N/A	-20	N/A	-17	N/A
3/31/2017	N/A	-19	N/A	-15	N/A
12/31/2016	N/A	-19	N/A	-15	N/A
9/30/2016	N/A	-18	N/A	-14	N/A
6/30/2016	N/A	-17	N/A	-14	N/A
3/31/2016	N/A	-15	N/A	-12	N/A
12/31/2015	N/A	-12	N/A	-9	N/A
9/30/2015	N/A	-10	N/A	-8	N/A
6/30/2015	N/A	-9	N/A	-6	N/A
3/31/2015	N/A	-12	N/A	-6	N/A
12/31/2014	N/A	-10	N/A	-5	N/A
9/30/2014	N/A	-6	N/A	-4	N/A
6/30/2014	N/A	-3	N/A	-3	N/A
3/31/2014	N/A	5	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALDX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: ALDX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ALDX is expected to become profitable in the next 3 years.

Revenue vs Market: ALDX's revenue (55.5% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: ALDX's revenue (55.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ALDX is forecast to be unprofitable in 3 years.

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 00:32
End of Day Share Price	2024/12/26 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aldeyra Therapeutics, Inc. is covered by 22 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Raghuram Selvaraju	Aegis Capital Corporation
Keay Nakae	Ascendiant Capital Markets LLC
Esther Lannie Hong	Berenberg

Aldeyra Therapeutics Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Price target increased by 8.1% to US$10.00

Consensus EPS estimates fall by 209%

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.18 loss

Forecast to breakeven in 2026

Consensus EPS estimates fall by 163%

Recent updates

New minor risk - Profitability

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Chief Development Officer recently sold US$76k worth of stock

Chief Development Officer notifies of intention to sell stock

Price target increased by 8.1% to US$10.00

New minor risk - Share price stability

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Consensus EPS estimates fall by 209%

New minor risk - Profitability

No longer forecast to breakeven

Aldeyra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Consensus EPS estimates upgraded to US$0.18 loss

Forecast to breakeven in 2026

Consensus EPS estimates fall by 163%

Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

No longer forecast to breakeven

New minor risk - Profitability

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

New minor risk - Profitability

No longer forecast to breakeven

Forecast to breakeven in 2024

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

CEO, President & Director recently sold US$581k worth of stock

CEO, President & Director notifies of intention to sell stock

Forecast to breakeven in 2024

New minor risk - Profitability

Forecast to breakeven in 2024

Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 55%

Consensus revenue estimates increase by 57%

Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

Consensus revenue estimates increase by 600%

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Consensus revenue estimates decrease by 82%, EPS upgraded

Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?

New minor risk - Market cap size

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Update of U.S. Food and Drug Administration Relating to the New Drug Application for Reproxalap for the Treatment of the Signs and Symptoms of Dry Eye Disease

Consensus revenue estimates decrease by 61%, EPS upgraded

Price target decreased by 13% to US$17.86

CEO, President & Director exercised options and sold US$492k worth of stock

Frank R. Cruz Announces Securities Fraud Lawsuit Against Aldeyra Therapeutics, Inc

Consensus revenue estimates increase by 36%

Consensus revenue estimates decrease by 73%, EPS upgraded

Holzer & Holzer, LLC Files Class Action Lawsuit Against Aldeyra Therapeutics, Inc

Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic Cough

Consensus revenue estimates increase by 15%

Aldeyra Therapeutics, Inc. Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE--2 Trial of Reproxalap in Allergic Conjunctivitis

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 30, 2023

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target increased by 8.4% to US$21.83

Aldeyra Therapeutics, Inc. Advances Investigational Oral RASP Modulator ADX--629 Into New Phase 2 Systemic Disease Trials

Aldeyra Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease

Forecast to breakeven in 2025

Insufficient new directors

Aldeyra Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Adx-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics, Inc. Announces Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial

Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Part 1 of Phase 3 Guard Trial of Adx-2191 in Proliferative Vitreoretinopathy

Aldeyra Therapeutics, Inc. Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA